Regression of Basal Cell Carcinomas in Multiple Sclerosis Patient on Aubagio Treatment

DeWitt, Judy Park; Thomas, Kleesy L; Sturgeon, Ashley

doi:10.12746/swrccc.v5i21.414

Cited by 2 publications

(2 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is noteworthy that many of the current DMTs have potential anti-tumor mechanisms. Examples, such as basal cell carcinoma improvement with terifluonomide treatment (134) suggest that a DMT should not be stopped at cancer diagnosis, but rather each individual's case should be considered in context of their specific risk factors for cancer. Thus, in making treatment decisions for MS patients with cancer, it is imperative that clinicians consider the potential mechanism of action of available DMTs to determine how best to manage both the cancer risk and the risk of rebound MS.…”

Section: Discussionmentioning

confidence: 99%

“…Teriflunomide may be an attractive anti-tumor medicine due to its efficacy at lower doses compared to other medications that inhibit DNA synthesis, such as methotrexate, and may thus avoid cumulative cytotoxic damage to the body (129). In particular, teriflunomide has been shown to improve basal cell carcinoma outcomes (134).…”

Section: Dna Synthesis Inhibitors: Teriflunomide (Aubagio) and Cladrimentioning

confidence: 99%

See 1 more Smart Citation

Multiple Sclerosis and Cancer: The Ying-Yang Effect of Disease Modifying Therapies

Melamed

Lee

2020

Front. Immunol.

View full text Add to dashboard Cite

Over the past two decades, the field of multiple sclerosis (MS) has been transformed by the rapidly expanding arsenal of new disease modifying therapies (DMTs). Current DMTs for MS aim to modulate innate and adaptive immune responses toward a less inflammatory phenotype. Since the immune system is also critical for identifying and eliminating malignant cells, immunosuppression from DMTs may predictably increase the risk of cancer development in MS patients. Compared with healthy controls, patients with autoimmune conditions, such as MS, may already have a higher risk of developing certain malignancies and this risk may further be magnified by DMT treatments. For those patients who develop both MS and cancer, these comorbid presentations create a challenge for clinicians on how to therapeutically address management of cancer in the context of MS autoimmunity. As there are currently no accepted guidelines for managing MS patients with prior history of or newly developed malignancy, we undertook this review to evaluate the molecular mechanisms of current DMTs and their potential for instigating and treating cancer in patients living with MS.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Dna Synthesis Inhibitors: Teriflunomide (Aubagio) and Cladrimentioning

confidence: 99%

Multiple Sclerosis and Cancer: The Ying-Yang Effect of Disease Modifying Therapies

Melamed

Lee

2020

Front. Immunol.

View full text Add to dashboard Cite

show abstract

Multiple sclerosis and cancer: Navigating a dual diagnosis

Nesbitt,

Van Der Walt,

Butzkueven

et al. 2024

Mult Scler

View full text Add to dashboard Cite

Healthcare breakthroughs are extending the lives of multiple sclerosis (MS) patients and cancer survivors, creating a growing cohort of individuals navigating a dual diagnosis. Determining the relationship between MS and cancer risk remains challenging, with inconclusive findings confounded by age, risk exposures, comorbidities, genetics and the ongoing introduction of new MS disease-modifying therapies (DMTs) across study periods. This research places significant emphasis on cancer survival, with less attention given to the impact on MS outcomes. Our review explores the existing literature on MS, cancer risk and the intersection of DMTs and cancer treatments. We aim to navigate the complexities of managing MS in cancer survivors to optimise outcomes for both conditions. Continuous research and the formulation of treatment guidelines are essential for guiding future care. Collaboration between neuro-immunology and oncology is crucial, with a need to establish databases for retrospective and ultimately prospective analysis of outcomes in these rapidly evolving fields.

show abstract

Regression of Basal Cell Carcinomas in Multiple Sclerosis Patient on Aubagio Treatment

Cited by 2 publications

References 2 publications

Multiple Sclerosis and Cancer: The Ying-Yang Effect of Disease Modifying Therapies

Multiple Sclerosis and Cancer: The Ying-Yang Effect of Disease Modifying Therapies

Multiple sclerosis and cancer: Navigating a dual diagnosis

Contact Info

Product

Resources

About